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Ribonuclease H2 (RNase H2) is the major nuclear enzyme
involved in the degradation of RNA/DNA hybrids and removal
of ribonucleotides misincorporated in genomic DNA. Muta-
tions in each of the three RNase H2 subunits have been impli-
cated in a human auto-inflammatory disorder, Aicardi-Gout-
ie`res Syndrome (AGS). To understand how mutations impact
on RNase H2 function we determined the crystal structure of
the human heterotrimer. In doing so, we correct several key
regions of the previously reported murine RNase H2 atomic
model and provide biochemical validation for our structural
model. Our results provide new insights into how the subunits
are arranged to form an enzymatically active complex. In par-
ticular, we establish that the RNASEH2A C terminus is a eu-
karyotic adaptation for binding the two accessory subunits,
with residues within it required for enzymatic activity. This
C-terminal extension interacts with the RNASEH2C C termi-
nus and both are necessary to form a stable, enzymatically ac-
tive heterotrimer. Disease mutations cluster at this interface
between all three subunits, destabilizing the complex and/or
impairing enzyme activity. Altogether, we locate 25 out of 29
residues mutated in AGS patients, establishing a firm basis for
future investigations into disease pathogenesis and function of
the RNase H2 enzyme.
RNA/DNA hybrids occur during fundamental cellular pro-
cesses, such as DNA replication (1), transcription (2), and te-
lomere elongation (3). Ribonuclease H2 (RNase H2)5 is the
predominant nuclear enzyme to hydrolyze the RNA strand of
such RNA/DNA hybrids. In addition, RNase H2 is able to
cleave the 5-phosphodiester bond of one or more ribonucle-
otides embedded in a DNA duplex (4, 5). As misincorporated
ribonucleotides may be the most abundant non-canonical
nucleotides present in genomic DNA (6), their removal by
factors including RNase H2 is likely to be critical to maintain
genomic integrity.
Eukaryotic RNase H2 has evolved markedly from its pro-
karyotic ancestry. In both archaea and bacteria, the RNase H2
enzyme consists of a single protein, while eukaryotic RNase
H2 is a complex containing three protein subunits, all of
which are required for activity (5). The RNASEH2A subunit
exhibits significant sequence homology, including the cata-
lytic site residues, with the prokaryotic enzyme, whereas the
two auxiliary subunits (RNASEH2B and RNASEH2C) have no
known prokaryotic equivalents. The precise role of the auxil-
iary subunits is not fully defined; however they are thought to
serve as a platform for assembly of the RNase H2 complex
and to modulate its interaction with other proteins. Indeed,
RNASEH2B binds PCNA (7), which is a scaffold and catalyst
for DNA-editing enzymes during DNA replication and repair
(8).
Mutations in all three subunits of human RNase H2 cause
the autoinflammatory disorder Aicardi-Goutie`res Syndrome
(AGS) (9, 10). AGS is an early-onset progressive encephalopa-
thy with similarities to congenital viral infections and shows
immunological features similar to those seen in the autoim-
mune disease systemic lupus erythematosis (11). Inflamma-
tion may be triggered by accumulation of nucleic acid byprod-
ucts from recently replicated DNA (12), or by increased
cellular levels of endogenous retroelements (13). Elevated lev-
els of these cytosolic nucleic acids are thought to be recog-
nized by pattern recognition receptors, which normally act to
detect viral infections (13).
Recently, the structure of the murine RNase H2 trimer was
solved (14). Despite a high degree of sequence identity be-
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tween the mouse and human subunits, the authors only lo-
cated three patient mutations in their structure, stating that
the remaining mutations were in disordered loops. We there-
fore determined the structure of the human RNase H2 trimer
to enhance our understanding of how RNase H2 mutations
cause disease. We report the crystal structure of human
RNase H2 at 4.1 Å resolution. We find that the core of the
catalytic domain adopts a canonical RNase H2 fold (15) simi-
lar to murine RNASEH2A (14), however we report a different
arrangement of the RNASEH2B and RNASEH2C subunits. In
addition, we define a more extensive interaction interface for
the C terminus of RNASEH2A that involves both auxiliary
subunits. Using biochemical assays, we demonstrate that the
C termini of RNASEH2A and RNASEH2C form an integral
component of the heterotrimer architecture and are impor-
tant for RNase H2 enzymatic function. Our human structure
now allows the mapping of 25 out of 29 AGS mutations, and
shows that 7 of these cluster at the interface of the
RNASEH2A and RNASEH2C C-terminal regions.
EXPERIMENTAL PROCEDURES
Cloning, Protein Expression, and Purification—A polycis-
tronic construct based on pGEX6P1 was made to express the
human RNase H2 trimer, allowing simultaneous expression of
GST-tagged RNASEH2B, and untagged RNASEH2A and
RNASEH2C (supplemental Fig. S1A). Shine-Dalgarno (SD)
sequences were introduced by PCR before RNASEH2A and
RNASEH2C coding sequences. Similar polycistronic con-
structs were used for all co-expression, with RNASEH2A,
RNASEH2B, or RNASEH2C replaced by alternative coding
sequences. Point mutations and internal deletions were intro-
duced using the QuikChange method (Stratagene); C-termi-
nal deletions were created with alternative reverse primers;
chimeric Archaeoglobus fulgidus (Afu)/human RNASEH2A
was generated by overlap PCR. For a list of constructs gener-
ated, see supplemental Table S1.
Recombinant RNase H2 complexes were expressed in Ro-
setta-2 cells (Novagen). Cells were grown to an optical density
of 0.6 at 37 °C, cooled to room temperature, and induced with
0.1 mM IPTG at 20 °C for 14–16 h. Cells were pelleted and
lysed by sonication in a PBS buffer containing 0.2% Tween, 10
mM MgCl2, Protease Inhibitor Mixture (Sigma, 50 l per
gram of cell pellet), 100 g of DNase I and 100 g of RNase A
(Sigma). Cleared lysates were incubated with glutathione-
Sepharose 4B beads (GE Healthcare Life Science) for 2 h at
16 °C. GST-tagged and associated proteins were released from
the beads by cleavage with PreScission protease (GE Health-
care Life Sciences) for 14–16 h at 4 °C and further purified by
size-exclusion chromatography in 150 mM NaCl, 20 mM Tris-
HCl pH 7.
Crystallization, Data Collection, and Refinement—As hu-
man RNaseH2 containing full-length subunits did not yield
crystals of sufficient quality, we improved x-ray diffraction by
truncating regions of predicted disorder and introducing
point mutations. Our best diffraction data were obtained from
crystals of a complex containing RNASEH2B residues 2–226,
full-length RNASEH2C, and RNASEH2A with catalytic site
mutations D34A and D169A. Importantly, this complex
(without the point mutations) retains the same activity as
wild-type RNase H2 (supplemental Fig. S1, B and C).
Crystals were grown by vapor diffusion at room tempera-
ture in 96-well plates with 0.2 l droplets at 4 °C. Equal vol-
umes of pre-formed RNaseH2 complex (11 mg/ml in 150 mM
NaCl, 20 mM Tris, pH 7) and precipitant (20% PEG3350, 0.1 M
bis-Tris-propane pH 6.5, 0.2 M KNO3) were mixed. Crystals
were cryoprotected with reservoir solution plus 20% ethylene
glycol before cryocooling in liquid nitrogen.
Diffraction data were collected at Diamond Light Source
(Harwell Science and Innovation Campus, UK) at beamline
I04. The data set was integrated and scaled using HKL2000
(16). Pseudo-translational symmetry was detected from a na-
tive Patterson map, and as a result MOLREP was used for the
molecular replacement strategy (17). Coordinates deposited
for the murine RNase H2 (PDB ID: 3KIO) were initially used
as a search model for phasing, however limited refinement
into the human electron density resulted in poor geometry
and statistics (supplemental Table S2). The deposited murine
structure was re-refined against deposited structure factors
with BUSTER-TNT (18), using non-crystallographic local
structure similarity restraints (19) and TLS constraints (where
each chain corresponded to a TLS group; supplemental Table
S3). As murine RNase H2 (PDB ID: 3KIO) was solved by ex-
perimental phasing using selenomethionine derivates (14), we
preserved the location but not necessarily the sequence con-
text of these methionines, including those introduced by site-
directed mutagenesis (14).
The re-refined murine RNase H2 coordinates were then
used as a molecular replacement model for the human struc-
ture. To generate a human homology model as a starting
point for refinement, point mutations were introduced using
COOT into the murine coordinates. Atomic models for the
subunits were refined against the 4.1 Å human dataset as indi-
vidual rigid bodies with PHENIX (20), followed by further
cycles of maximum-likelihood positional and B-factor refine-
ment with BUSTER-TNT (18) using TLS and 2-fold NCS re-
straints. The use of non-crystallographic local structure simi-
larity restraints (19) plus strict stereochemical (18) and
B-factor (21) restraints were coupled with highly conservative
rebuilding to avoid over-fitting of the experimental data. Be-
cause of steric clashes, RNASEH2A:143–166 were excluded
from the refinement in one of the two heterotrimers. The
analysis and figures presented were generated from the het-
erotrimer best-resolved in electron density. Final refinement
statistics are reported in Table 1.
Protein Co-precipitation—Recombinant complexes with
one subunit GST-tagged were expressed using polycistronic
constructs and purified by affinity chromatography (see
above). Affinity-matrix-bound proteins before and after Pre-
Scision Protease cleavage were separated by SDS-PAGE (12%)
and visualized by Coomassie Brilliant Blue staining.
RNase H2 Activity Assay—Enzyme activity assays were per-
formed using a fluorometric assay as previously described (9).
Briefly, 10 M of 3 fluorescein-labeled oligonucleotides
(GATCTGAGCCTGGGaGCT or gatctgagcctgggagct; upper-
case DNA, lowercase RNA) were annealed to a complemen-
tary 5 DABCYL-labeled DNA oligonucleotide (Eurogentec)
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in 60 mM KCl, 50 mM Tris-HCl, pH 8, by heating for 5 min at
95 °C followed by slow cooling to room temperature. Reac-
tions were performed in 100 l of buffer (60 mM KCl, 50 mM
Tris-HCl, pH 8, 10 mM MgCl2, 0.01% BSA, 0.01% Triton
X-100) with 250 nM substrate in 96-well flat-bottomed plates
at 24 2 °C for 90 min. Fluorescence was read for 100 ms
using a VICTOR2 1420 multilabel counter (Perkin Elmer),
with a 480 nm excitation filter and a 535 nm emission filter.
Reactions were carried out in triplicate with a range of differ-
ent protein concentrations. A standard curve (relating fluo-
rescence units to moles of converted substrate) was generated
using fluorescein-labeled oligonucleotide annealed to DNA
without DABCYL.
Steady State Enzyme Kinetics—Experiments were per-
formed using the fluorometric assay and conditions described
above, with 0.1 nM RNase H2 and substrate concentrations
ranging from 0 to 1 M for RNA18:DNA18 substrate or from 0
to 0.5 M for D14R1D3:D18 substrate. Initial velocities of sub-
strate cleavage were determined and expressed as the rate of
the converted substrate concentration (nM) over time (min).
Substrate hydrolysis by RNase H2 follows Michaelis-Menten
kinetics. Kinetic parameters Km and Vmax were determined
using non-linear regression in SigmaPlot 11.0 (Systat Software
Inc.).
ThermoFluor Assay—Thermal stability assays were per-
formed using the fluorescence-based thermal shift (Thermo-
Fluor) method as previously described (22). Proteins were
diluted in 50 l volumes to 2 M in 10 mM HEPES-KOH pH
7.2, 100 mM potassium acetate, 2 mM magnesium acetate, and
5 SYPRO Orange (Invitrogen). Assays were carried out in a
Bio-Rad iQ5 rtPCR Thermocycler, heating the samples from
20 °C to 80 °C at 0.5 °C increments, holding each temperature
for 30 s. Fluorescence intensity was measured in relative fluo-
rescence units (RFU) using excitation/emission wavelengths
of 485 nm/575 nm. Thermal denaturation graphs were plot-
ted as a function of the gradient of protein unfolding [d(RFU)/
dT] against the temperature gradient, with the melting tem-
perature (Tm) defined as the temperature at the maximum of
d(RFU)/dT.
Peptide Arrays—Peptides were generated by automatic syn-
thesis (23, 24) on chemically modified cellulose membrane
disks derivatized with Fmoc--alanine using standard Fmoc
(fluoren-9-ylmethoxycarbonyl) chemistry with the MultiPep
(Intavis Bioanalytical Instruments AG) (23, 25). After synthe-
sis, side chains were deprotected by incubating the disks in
80% trifluoroacetic acid (TFA), 3% triisopropylsilane (TIPS),
5% H2O, 12% dichloromethane for 1 h at room temperature.
This solution was removed and the membrane disks were sol-
ubilized in 88.5% TFA, 4% trifluoromethanesulfonic acid,
2.5% TIPS, 5% H2O for 16 h at room temperature. Peptide-
cellulose conjugates were precipitated with ice-cold tert-bu-
tylmethylether, dried, and dissolved in DMSO. Peptide arrays
were created by spotting the peptide-cellulose conjugates on
coated microscope slides (CelluSpotsTM, Intavis Bioanalytical
Instruments AG) in duplicate.
Slides were blocked in TBST (50 mM Tris pH 7.5, 150
mM NaCl, 0.05% Tween-20) containing 5% BSA and then
overlaid with TBST/0.5% BSA containing 0.4 M recombi-
nant His-RNASEH2BC. Control slides were overlaid with
TBST/0.5% BSA only. Bound protein was detected with
anti-His-HRP (Qiagen) and visualized by ECL (GE Health-
care Life Sciences).
Fluorescence Anisotropy—Peptide binding experiments
were performed at 20 °C in a Perkin Elmer LS55 Lumines-
cence Spectrometer with excitation/emission wavelengths of
480 nm/530 nm and slit widths of 15 nm/20 nm, respectively.
The photomultiplier voltage used was 650 V with an integra-
tion time of 5 s per measurement. A peptide corresponding to
the C terminus of RNASEH2A with an N-terminal fluorescein
plus a single glycine linker ([Fluorescein] GSSHRYFLERGLE-
SATSL; Peptide Protein Research) was rehydrated in 150 mM
NaCl, 20 mM Tris, pH 8 and diluted in a 900 l volume to a
final concentration of 20 nM. The RNASEH2BC heterodimer
(54.4 M) was titrated into a constantly stirred cuvette con-
taining the fluorescein-labeled peptide. Anisotropy was mea-
sured continuously, and the values recorded once measure-
ments were unchanged for five consecutive readings.
Dissociation constants (Kd) were calculated by fitting the ti-
tration data (corrected for dilution) to a one-site binding
equilibrium model in Prism5 (GraphPad Software).
RESULTS
Crystal Structure of the Human RNase H2 Complex—To
gain insight into how mutations in RNase H2 cause human
disease, we set out to solve the structure of the human RNase
H2 heterotrimer. Given significant sequence conservation
between human and murine RNase H2 (86, 80, and 65%
sequence identity for RNASEH2A, RNASEH2B, and
RNASEH2C, respectively) the murine RNase H2 crystal struc-
ture (PDB ID: 3KIO) (14) was used as a model for molecular
replacement to phase human RNase H2. However, limited
refinement of this solution into the human RNase H2 electron
density failed to give adequate statistics or geometry
TABLE 1
X-ray data collection and refinement statistics for human RNase H2
Human RNaseH2
Data collection
Space group C2
Cell dimensions
a, b, c (Å) 212.2, 42.3, 186.9
, ,  (°) 90.0, 98.1, 90.0
Resolution (Å) 29.8-4.1 (4.4-4.1)a
Rmerge 0.18 (0.69)
I/(I) 5.6 (1.7)
Completeness (%) 98.5 (98.7)
Redundancy 3.9 (3.5)
Refinement
Number of reflections 13281 (2371)
Rxpctb 37.4 (28.7)
Rfree 37.9 (28.0)
Number of non-H atoms 7359
Rmsd
Bond lengths (Å) 0.008
Bond angles (°) 0.96
Ramachandran plot
Favored (%) 94.1
Outliers (%) 0.5
Average B factors (Å2) 188.1
a Values in parentheses are for highest-resolution shell.
bRxpct 100 (hkl Fobs Fxpct/hkl Fobs), where Fobs and Fxpct are the
observed structure factor amplitude and the expectation of the model structure
factor amplitude, respectively (18).
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(supplemental Table S2). Re-analysis of the coordinates and
structure factors deposited in the Protein Data Bank (PDB)
for murine RNase H2 established that the published mouse
model was not in agreement with the experimental electron
density in a number of areas (mRNASEH2C residues 87–116
and 136–144; mRNASEH2B residues 92–102, 146–159, and
267–282; supplemental Fig. S2 and S3) (26). We therefore
used BUSTER-TNT to re-refine the deposited murine coordi-
nates against the deposited structure factors. Our new inter-
pretation of the murine model improved the refinement sta-
tistics (supplemental Table S3) and produced a better visual
fit to the density (supplemental Fig. S3). The two murine
models are similar in their secondary structural elements but
differ significantly in their connectivity and sequence assign-
ment for all three RNase H2 subunits (see supplemental Fig.
S3 and S4, and supplemental text for a detailed description of
the differences observed).
We then solved the structure of human RNase H2 to 4.1 Å
resolution by molecular replacement using coordinates for
this re-refined murine model. To avoid overfitting of the data,
the human model was refined using tight geometric and B-
factor restraints (21) resulting in refinement residuals Rexpt
and Rfree of 37.4 and 37.9%, respectively. The geometry of the
final refinement was assessed using MOLPROBITY (27).
94.1% of the residues were in the favored region of the Ram-
achandran plot; 0.5% were outliers.
As expected from the sequence conservation between mu-
rine and human RNase H2, we find their structures to be sim-
ilar. Superposition of atomic models based on secondary
structure matching (28) resulted in a root mean square devia-
tion of 1.01 Å for equivalent C atom pairs. The largest differ-
ence was found at (human) RNASEH2A residues 195–204.
However, due to the low resolution of our human structure,
this new conformation was not modeled and the -helix was
truncated at residue 194.
Human RNase H2 is a heterotrimeric complex in which the
core domains of the three subunits are linearly stacked (Fig.
1A). The structure of the RNase H2 catalytic subunit is highly
conserved between prokaryotes and eukaryotes (14, 15). In-
deed, we find that the core domain of human RNASEH2A
adopts a canonical RNase H2 fold. In eukaryotes, the se-
quence of RNASEH2A extends beyond the catalytic core do-
main to include nearly 50 additional residues. Whereas resi-
dues 258–283 are not resolved in our human RNase H2
structure, the extreme C terminus of RNASEH2A (residues
284–299) forms an /motif that binds the RNASEH2BC
heterodimer, and RNASEH2A residues 250–257 contribute
to a -sheet with RNASEH2C. The auxiliary RNASEH2B and
RNASH2C subunits together with the C-terminal extension
of RNASEH2A adopt an interwoven triple -barrel fold cen-
tered on the C-terminal half of RNASEH2C. RNASEH2C resi-
dues 118–126 and 128–134 form -strands central to all
three -barrels, whereas residues 143–160 form a kinked
-helix that interacts with secondary structure elements of
RNASEH2B and the C terminus of RNASEH2A.
Analysis of the electrostatic surface potential of RNase H2
reveals two positively charged patches on the same face of the
molecule (Fig. 1B). The first region corresponds to the active
site binding groove of the catalytic RNASEH2A subunit and is
similar to that observed for Archaeoglobus fulgidus (Afu)
RNase HII (15). The second basic patch occurs in the vicinity
of the central -barrel formed by the RNASEH2B and
RNASEH2C subunits, and may indicate an additional sub-
strate binding site.
The RNASEH2A C Terminus Is Necessary for an Enzymati-
cally Active Complex—In the crystal structure of human
RNase H2 the C terminus of RNASEH2A extends from the
FIGURE 1. Crystal structure of the heterotrimeric RNase H2 complex.
A, ribbon diagram representation of human RNase H2 reveals a linear ar-
rangement of subunits where the core of the catalytic domain (RNASEH2A;
blue) is stacked on the interwoven auxiliary RNASEH2B (green) and
RNASEH2C (red) subunits. The C terminus of RNASEH2A, residues 284–299
(blue arrow), extends from the core domain and bridges the other two sub-
units. The first residue of the extension, RNASEH2A:284, and the last residue
of the core domain, RNASEH2A:257, are indicated by gray and blue asterisks,
respectively. The C terminus of RNASEH2C (red arrow) forms a kinked -he-
lix at the intersubunit interface. B, electrostatic surface of human RNase H2
indicates two positively charged patches: one in the catalytic active site
groove (gray arrow) and the second on the interwoven RNASEH2BC het-
erodimer (black arrow). Electrostatic surface potential was calculated using
PDB2PQR (34) and colored by potential (9kT/e to9 kT/e; electropositive
in blue and electronegative in red) on the solvent accessible surface using
the APBS tool (35). These and all other molecular graphics were generated
using PyMOL (DeLano Scientific LLC).
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core catalytic domain and bridges the two auxiliary subunits
(Fig. 2A). To assess the functional relevance of this interac-
tion, we examined the effect of mutant and chimeric
RNASEH2A on complex assembly and enzyme activity. GST-
tagged RNASEH2B was used to co-purify complexes by
affinity chromatography. When co-expressed, wild-type
RNASEH2A, RNASEH2B, and RNASEH2C subunits assemble
to form an enzymatically active complex (Fig. 2). In contrast,
deletion of the RNASEH2A C-terminal extension (residues
248–299; RNASEH2AC) entirely abolished heterotrimer
formation, resulting in isolation of the RNASEH2BC het-
erodimer only (RNASEH2ACBC; Fig. 2B). RNASEH2AC
could be purified (supplemental Fig. S5), indicating that lack
of assembly was not due to misfolding of the truncated pro-
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tein. Proteins purified after RNASEH2ACBC expression did
not exhibit enzyme activity (data not shown). This is in agree-
ment with the requirement for all three subunits for substrate
cleavage by eukaryotic RNase H2 (5, 7). However, in vivo as-
sembly is not a pre-requisite for an enzymatically active com-
plex, as we could reconstitute RNase H2 activity by mixing
recombinant RNASEH2A with separately purified
RNASEH2BC in vitro (Fig. 2C). In contrast, mixing of
RNASEH2AC with RNASEH2BC did not show activity above
background (Fig. 2C). We therefore conclude that the
RNASEH2A C terminus is essential for the formation of an
enzymatically active RNase H2 heterotrimer.
The C Terminus of RNASEH2A Is a Eukaryotic Adaptation
Allowing Binding of Accessory Subunits—Prokaryotes which
lack the auxiliary RNASEH2B and RNASEH2C subunits also
lack the C-terminal extension of RNASEH2A present in eu-
karyotes. It is therefore not surprising that Afu RNase HII is
unable to bind the human RNASEH2BC heterodimer despite
sharing 27% sequence identity with human RNASEH2A (Fig.
2D). In contrast, a chimeric Afu RNase HII to which C-termi-
nal residues 248–299 of human RNASEH2A were fused al-
lowed efficient heterotrimer formation (Fig. 2D). This com-
plex was able to cleave RNase H2 substrates (though with
reduced activity compared with Afu RNase HII alone; Fig. 2E).
Furthermore, murine RNASEH2A could bind human
RNASEH2BC (Fig. 2D), showing that residues essential for
interaction are conserved between the mouse and human cat-
alytic subunits. This mouse/human chimeric RNase H2 was
functional and exhibited enzyme activity similar to both wild-
type mouse and human RNase H2 (Fig. 2E).
RNASEH2A Residues Critical for Interaction with the Acces-
sory Subunits—The extended C terminus of RNASH2A is
central to the inter-subunit triple -barrel architecture
formed between all three RNase H2 subunits. As the chain
tracing of this region (RNASEH2A:284–299) differs from that
previously reported for murine RNase H2 (14), we performed
biochemical and biophysical assays to corroborate our atomic
model. In addition, these assays define specific residues in-
volved in the interaction between the RNASEH2A C terminus
and the accessory subunits.
Firstly, to confirm binding of the C-terminal 17 residues of
RNASEH2A to the RNASEH2BC heterodimer, we assessed
the anisotropy of a fluorescein-labeled peptide (RNASEH2A:
283–299) in the presence of increasing concentrations of
RNASEH2BC heterodimer (Fig. 2F). The peptide bound the
heterodimer both with high affinity and specificity (Kd
123 10 nM), and the addition of purified full-length
RNASEH2A successfully competed for RNASEH2BC binding
while the RNASEH2AC C-terminal truncation mutant had
no effect (data not shown).
Secondly, peptide arrays were used to examine the
interaction between the RNASEH2A C terminus and the
RNASEH2BC heterodimer in more detail. Use of such peptide
arrays has proved an accurate method for the mapping of pro-
tein-protein interactions (29, 30). RNASEH2A peptides cover-
ing residues Ile-253–Ala-259 and Tyr-287–Leu-299 were suf-
ficient to bind RNASEH2BC (Fig. 2G and supplemental Fig.
S6A). Furthermore, systematic mutational analysis of a pep-
tide corresponding to RNASEH2A:275–299 identified resi-
dues Tyr-287, Phe-288, Arg-291, Leu-293, and Ala-296 as
essential for binding (Fig. 2G). This is in agreement with our
structural model, which shows direct involvement for the side
chains of these amino acids in inter-subunit interactions. All
of these residues are conserved between human and mouse
(Fig. 2H), consistent with the formation of a functional com-
plex between mouse RNASEH2A and human RNASEH2BC.
Significantly, substitution of one of these residues (Arg-291)
has been found to cause AGS (10).
Furthermore, though unresolved in our crystal structure,
peptide array analysis indicates that RNASEH2A residues
Gly-264—Thr-270 are also involved in RNASEH2BC binding.
We show that Arg-266 and Lys-267 are essential for binding,
and mutagenesis of these two residues (R266A/K267A) in
recombinant RNase H2 leads to reduced enzyme activity,
without affecting complex stability (supplemental Fig. S6). In
conclusion, our data demonstrate that the RNASEH2A C ter-
minus has a key role in enzyme function, being critical both
for complex formation and enzymatic activity.
RNASEH2C as a Platform for Complex Assembly—The hu-
man RNase H2 structure shows that the C terminus of
RNASEH2C (Arg-118—Gln-160) forms an integral compo-
nent of the heterotrimer architecture. Residues in the C-ter-
minal kinked helix (RNASEH2C:143–160) contact both
RNASEH2A and RNASEH2B, while -strands formed by
FIGURE 2. The C terminus of RNASEH2A is essential and sufficient for its interaction with RNASEH2B and -C. A, surface representation of the interface
between human RNASEH2B (green), RNASEH2C (red) and the C terminus of RNASEHA:284–299 (blue ribbon). Amino acids found to be essential for binding
in the peptide array (Tyr-287, Phe-288, Arg-291, Leu-293, Ala-296) are shown as sticks. B, Coomassie Blue stained SDS-PAGE gels show purification of GST-
tagged RNASEH2B (GST-B) and associated proteins. Schematics illustrate subunit compositions of expressed complexes. Complexes composed of full-
length subunits (RNASEH2ABC or RNASEH2BC) or with RNASEH2A truncated after residue 247 (RNASEH2ACBC) were bound to glutathione-Sepharose
(bound) and released by cleavage with Precision Protease (cleaved). C, reconstitution of enzyme activity after mixing of RNASEH2A and RNASEH2BC in vitro.
RNA18:DNA18 substrate was cleaved with increasing concentrations of purified proteins. BC (dashed lines) indicates addition of RNASEH2BC heterodimer;
RNASEH2Acat and RNASEH2AcatBC indicate D34A and D169A point mutations in RNASEH2A (catalytically inactive); RNASEH2AC indicates truncated
RNASEH2A:1–247; mock indicates background activity from the cleaved fraction of a GST-only purification. D, affinity purification after co-expression of hu-
man GST-RNASEH2B and RNASEH2C with either murine RNASEH2A (RNASEH2mmA-hsBC), A. fulgidus RNaseHII (RNASEH2Afu-hsBC) or Afu RNaseHII fused to
residues 248–299 of human RNASEH2A (RNASEH2Afu-hsAC-BC). E, cleavage of D14R1D3:D18 substrate by chimeric RNase H2 complexes described under D,
as well as wild-type human RNase H2 (RNASEH2ABC), murine RNase H2 (mmRNASEH2ABC) and A. fulgidus RNaseHII (Afu RNASEH2). F, fluorescence anisot-
ropy of a fluorescein-labeled peptide (RNASEH2A:283–299) as a function of increasing concentrations of RNASEH2BC. G, peptide array corresponding to
RNASEH2A residues 275–299 probed with His-tagged RNASEH2BC and anti-His-HRP. Alanine point mutations are printed in red; RNASEH2A residues essen-
tial for binding are indicated in bold; “antibody only” shows background binding of anti-His-HRP to the array. H, sequence alignment for human (Hs) and
Mus musculus (Mm) RNASEH2A with RNase HII from Archeoglobus fulgidus (Afu_rnhB). Secondary structure elements for human RNASEH2A are shown in
blue (arrows for -strands; loops for -helices). The vertical black arrowmarks where RNASEH2AC was truncated; dark blue boxes highlight peptides suffi-
cient for binding RNASEH2BC; dark blue arrowheads indicate residues essential for binding in the peptide arrays described above; * mark residues mutated
in AGS. This and all other sequence alignments were generated using ALINE (36).
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RNASEH2C residues Arg-118—Phe-126 and Arg-128—Leu-
134 are part of two central -sheets which contribute to the
inter-subunit -barrel architecture (Fig. 3A). Given that the
chain tracing of this entire region (RNASEH2C: 87–160) is
completely different from that previously reported for murine
RNase H2 (14), we proceeded to confirm the functional rele-
vance of the interaction interfaces defined by our structure.
We examined complex integrity and enzyme activity of a de-
letion mutant lacking the C-terminal residues 117–164 of
human RNASEH2C (residues that our human structure pre-
dicts are integral to heterotrimer formation). Removal of
these residues abolished heterotrimer formation (Fig. 3B;
RNASEH2ABCC) and over 99.5% of enzyme activity was lost
(Fig. 3C). In contrast, deletion of RNASEH2C residues Val-
91—Phe-116 had no effect on complex stability or enzymatic
function: all three subunits were purified in equimolar
amounts (Fig. 3B; RNASEH2ABC91–116) and exhibited en-
zyme activity similar to that of wild-type RNase H2 (Fig. 3C).
The previously published murine RNase H2 structure pre-
dicted that these residues should be critical for complex for-
mation as they were central to the interwoven triple -barrel
fold (14). However, in our human and re-refined murine
structures these residues were not modeled and we predicted
them to form a disordered loop. Comparative sequence analy-
sis shows that residues 91–111 are poorly conserved in mam-
mals, in contrast with the rest of the RNASEH2C protein and
the extreme C terminus in particular (Fig. 3D). Therefore, our
structural, biochemical and primary sequence analyses are all
consistent with RNASEH2C residues 87–117 forming a disor-
dered loop, while RNASEH2C residues 118–160 comprise an
integral part of the heterotrimer, essential for complex forma-
tion and enzymatic activity.
Structural Implications of AGS Mutations—Point muta-
tions in all three subunits of RNase H2 cause the auto-in-
flammatory disorder AGS, although it remains uncertain
how these amino acid substitutions cause disease (7, 31).
We are now able to assign 25 of the 29 disease-causing sub-
stitutions to the human structure (Fig. 4A), and find that a
significant number of affected residues cluster in and
around the C termini of the RNASEH2A and RNASEH2C
subunits (Fig. 4B), regions we show to be critical for het-
erotrimer formation.
This region contains seven affected residues: five in
RNASEH2C (R69W, P76L, P138L, K143I, and P151S), one in
RNASEH2A (R291H) and one in RNASEH2B (A177T). These
all influence the geometry of a kinked helix at the RNASEH2C
C terminus. Firstly, we predict that the R69Wmutation will
disrupt the orientation of an RNASEH2C -strand that packs
against the kinked helix, as the Arg-69 side chain forms a salt-
bridge with mRNASEH2C:D55 in the murine structure (Fig.
4B, right panel), anchoring it to a core -sheet. Although the
aspartic acid at Asp-55 is not conserved in humans, two other
negatively charged amino acids (Glu-57 and Glu-60) are avail-
able to bind this arginine residue.
FIGURE 3. The RNASEH2C C terminus, but not residues 91–116, are essential for complex formation and enzyme activity. A, RNASEH2C (red and pink
ribbons), together with RNASEH2A (blue ribbons) and RNASEH2B (green ribbons), form a triple -barrel. End points of the disordered loop in RNASEH2C
(residues Thr-86 and Arg-118) are indicated. The chain is continuous from residue Arg-118 to Gln-160 (pink ribbon). B, Coomassie Blue-stained SDS-PAGE
gels show purification of GST-tagged RNASEH2B (GST-B) and associated proteins. Affinity purification after coexpression of GST-RNASEH2B and RNASEH2A
with either RNASEH2CC (left panel) or RNASEH2C91–116 (right panel). C, RNASEH2ABC91–116 shows the same activity as wild-type RNase H2 (RNASEH2ABC).
In contrast, RNASEH2ABCC is more than 100-fold less active. Point mutations D34A/D169A (RNASEH2AcatBC) abolish all detectable RNase H2 activity.
D, sequence alignment for human (Hs),Mus musculus (Mm), Canis familiaris (Cf), and Bos taurus (Bt) RNASEH2C. Secondary structure elements for human
RNASEH2C are shown in red (arrows for -strands; spirals for  helices). Themagenta boxmarks amino acids deleted in RNASEH2C91–116; the vertical black
arrowmarks where RNASEH2CC was truncated; * mark residues mutated in AGS.
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Secondly, three of the mutations (P76L, P138L, and
P151S) target proline residues at transition points between
secondary structure elements. Prolines have a unique
structural role due to their rigid backbone dihedral angle
enforced by a cyclic side chain. Together, the three affected
proline residues influence the geometry of the kinked helix:
Pro-138 commences the loop (138PGP140) that interrupts
the -turn preceding the kinked C-terminal helix; Pro-151
facilitates the bend, while its side chain packs against that
of Pro-76 (which initiates a loop, 76PPG78, that changes the
direction of a -strand).
Thirdly, side chains of two mutated residues (RNASEH2C:
K143 and RNASEH2A:R291) are involved in the binding of
RNASEH2A to the kinked helix. Lys-143 is located at the first
turn of the kinked helix and the amino group of its side chain
caps a short helix at the RNASEH2A C terminus, strengthen-
ing the RNASEH2A helix dipole. This interaction locks the
side chain of RNASEH2C:K143 into place, thus anchoring the
kinked helix. Notably RNASEH2A:R291 also forms part of
this interface, as its guanidinium group forms a salt bridge
with the backbone carbonyl oxygen of RNASEH2C:G146
(Arg-148 in mouse).
Finally, we predict the A177T mutation in RNASEH2B to
disrupt the interface between a RNASEH2B -helix and the
RNASEH2C kinked helix. The affected alanine residue sits in
a hydrophobic pocket and packs against RNASEH2C:A156
of the kinked helix. Notably, the A177T substitution in
RNASEH2B is the most common mutation, found in more
than a quarter of AGS patients (10).
In summary, we predict all seven residues to influence the
conformation of the RNASEH2C kinked helix and to have an
important role at an interface bridging all three subunits. We
would therefore expect mutations in these residues to reduce
stability of the RNase H2 complex; a prediction we assessed
using a fluorescence-based thermal shift assay, which mea-
sures the melting temperatures of purified recombinant hu-
man RNase H2 proteins. All seven AGS mutations caused
reduced thermal stability of recombinant RNase H2 complex
compared with wild-type RNase H2 (Fig. 4C). Furthermore,
with the exception of RNASEH2B:A177T and RNASEH2C:
P138L, mutations reduced cleavage of RNA/DNA hybrids
(Fig. 4D and data not shown). In contrast to the small effect
on the thermal stability of the complex, K143I and R291H had
the most pronounced effect on enzyme activity, with an 85
FIGURE 4. AGSmutations at the RNASEH2A/RNASEH2C interface lead to reduced protein stability and enzyme activity. A, crystal structure of human
RNase H2 is shown as ribbons and colored as in Fig. 1. Residues mutated in AGS are shown as yellow sticks. Nitrogen and oxygen atoms of highlighted resi-
dues are blue and red, respectively. B, close-up showing AGS affected mutations in the vicinity of the RNASEH2C C-terminal kinked helix. The left panel high-
lights residues in our human RNase H2 crystal structure while the right panel shows the corresponding residues for our re-refined murine model. (Arrows
indicate the direction of the helix dipole running from positive to negative). C, fluorescence-based thermal stability assay was used to measure the melting
temperatures of recombinant AGS mutant complexes. All mutations that cluster at the heterotrimer interface destabilize RNase H2. Error bars indicate the
standard deviation of 10 independent measurements. D, most of these AGS mutations also cause reduced enzyme activity. Cleavage of D14R1D3:D18 sub-
strate with increasing amounts of RNase H2 was measured in triplicate.
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and 94% reduction in specific activity respectively (Fig. 4D).
This is particularly striking given their distance from the cata-
lytic center and predicted substrate binding groove. Measure-
ments of enzyme kinetics for RNase H2 with K143I and
R291H mutations (Table 2) indicate that their enzyme activi-
ties are decreased due to reduced turnover (lower kcat) and
not reduced substrate affinity (no change in Km). In conclu-
sion, all these mutations either disrupt complex stability
and/or in vitro enzymatic activity. Atomic coordinates have
been deposited at the RCSB Protein Data bank under ID
codes 3P56 for human RNase H2 and 3P5J for the re-refined
murine RNase H2.
DISCUSSION
Our structure of the human RNase H2 complex identifies
novel structural elements of the RNASEH2BC heterodimer
and catalytic RNASEH2A subunit relevant to enzyme func-
tion and disease. We establish that the C-terminal extension
of RNASEH2A spans the two auxiliary subunits and is neces-
sary for the formation of an enzymatically active complex.
The C terminus of RNASEH2C also contributes to the unique
interwoven architecture of the heterotrimer, by forming a
helix that bridges the RNASEH2A and RNASEH2B subunits.
Analysis of human disease mutations that cluster in this re-
gion demonstrates the importance of this interface for com-
plex stability and enzymatic activity.
Role of the RNASEH2A C terminus in Enzymatic Activity—
Our data establish that the RNASEH2A C-terminal tail is
required for enzymatic activity. A unique adaptation of eu-
karyotic RNase H2 enzymes, this C-terminal tail permits en-
zyme activity only when accessory subunits are bound. Strik-
ingly, substitution of specific residues in this C-terminal
extension (R291H, K266A/R267A) impair enzyme activity,
with minimal or no effect on complex stability (Fig. 4 and
supplemental Fig. S6). Furthermore, mutation of a directly
interacting residue of the RNASEH2C subunit (K143I) has the
same effect. Notably, all these residues are distant from the
catalytic center. These residues may therefore influence en-
zyme activity by forming an additional substrate-binding site
distinct from the proposed RNASEH2A binding groove (14,
15). Alternatively, they could influence RNase H2 quaternary
structure to alter enzymatic activity.
Spatial and temporal regulation of DNA replication and
repair pathways is essential for genome stability in eukaryotic
cells. Intriguingly, the RNASEH2BC heterodimer can exist as
a stable subcomplex in vitro (Fig. 2) (7). As the RNASEH2A
protein is present at much lower levels than the other sub-
units,6 this catalytic subunit might bind only when and where
enzyme activity is required.
AGS Mutations Cause RNase H2 Dysfunction—We are able
to map the majority of AGS mutations onto the human RNase
H2 structure (86%). This provides a significant advance in
understanding the structural context of these mutations in
human disease. It is evident that some mutations directly af-
fect enzyme catalysis (7, 9, 31, 32). It has also been established
that other AGS mutations do not dramatically alter enzymatic
activity in vitro (7, 31) and our findings are consistent with
these studies. However, we find that mutations with no or
limited effects on in vitro enzyme activity (RNASEH2B:
A177T, and RNASEH2C:R69W, P76L, and P138L) signifi-
cantly destabilize the RNase H2 complex, as measured by a
reduction in thermal stability of recombinant RNase H2.
Though such instability does not necessarily have a direct in
vivo correlation, these mutations may lead to diminished
RNase H2 levels and impaired cellular activity. Hence, our
data are consistent with the notion that human mutations
cause AGS through reduced enzymatic activity, in an analo-
gous manner to disease mutations in TREX1 (33). Future ex-
amination of other human mutations may well provide addi-
tional insight into the biology of RNase H2. For instance,
mutations in surface residues (e.g. RNASEH2A:T240M,
RNASEH2B: K162T and V185G, and RNASEH2C:R13H)
could impair interactions with nucleic acid substrates or other
proteins.
In summary, our findings provide important structural in-
sight into the requirements for RNase H2 complex integrity
and regulation of enzyme activity, relevant to the cellular
process of RNA/DNA hybrid degradation and the pathogene-
sis of systemic autoimmune disease. Additionally, the struc-
ture of the RNase H2 complex provides a framework for fu-
ture investigation of RNase H2 function and its regulation in
the eukaryotic cell.
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